The team could further predict, with 82 percent accuracy,
which patients would respond to treatment with the antipsychotic medicine Risperidone.
The investigators hypothesized that“treatment with olanzapine and Risperidone would be associated with greater treatment response
and greater tolerability than treatment with molindone,” but that did not turn out to be the case.
On August 22, 2007, Risperidone was approved as the only drug agent
available for treatment of schizophrenia in youths, ages 13-17; it was also approved that same day for treatment of bipolar disorder in youths and children, ages 10-17, joining lithium.